Abstract 505P
Background
The RATIONALE-312 study reports PD-1 inhibitor (tislelizumab) plus platinum–etoposide could improve survival of patients with extensive-stage small-cell lung cancer (SCLC). Based on this, we initiated a pilot study to explore the safety and feasibility of neoadjuvant Tislelizumab plus platinum–etoposide in limited-stage SCLC.
Methods
Treatment-naïve limited-stage SCLC patients with ECOG PS 0-1 status were enrolled. Patients received 4 cycles of Tislelizumab (200mg, q3w) plus platinum (Cisplatin 75 mg/m2 or Carboplatin AUC5) – etoposide (100 mg/m2). The feasibility of surgery was then reassessed by radiology. Candidates for complete resection underwent surgery; otherwise, they received radiotherapy. Patients who received surgery also received adjuvant Tislelizumab plus platinum–etoposide therapy for 4 cycles. Primary endpoints were safety and feasibility. Secondary endpoints were objective response rate (ORR), pathologic response, and survival.
Results
A total of 8 eligible patients were enrolled up to April 2023. The median age was 65 (range: 57-70) with 6 male patients and 7 smokers. Among them, 1, 4, and 3 patients had stage ⅡB, ⅢA and ⅢB disease, respectively. No previously unreported toxic effects were observed. Treatment-related adverse events (TRAEs) of any grade occurred in 7 of 8 (87.5%) patients. Grade 3-4 events occurred in 6 of 8 (75%) patients. There were no severe adverse events. The majority of TRAEs was chemotherapy-related, and 2 patients suffered mild immune-related thyroid dysfunction. Seven patients completed 4 cycles of neoadjuvant therapy, and the best ORR was 85.7% (5 partial response and 1 stable disease). Of the 7 patients, 5 were assessed to be resectable. There were no treatment-related surgical delays. R0 resection and pathological downstaging were achieved for all 5 patients (100%) without any serious surgical complications. At a median of 18 months (range: 10 - 20) of follow-up, all patients were alive, and all the patients who received surgery were recurrence-free.
Conclusions
Neoadjuvant Tislelizumab plus platinum–etoposide was associated with tolerable side effects and was effective for patients with limited-stage SCLC.
Clinical trial identification
NCT04542369.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Pulmonary Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract